# A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

> **NCT05140096** · PHASE1 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Fluconazole
- **DRUG:** Isavuconazole

## Key facts

- **NCT ID:** NCT05140096
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-03
- **Primary completion:** 2020-04-15
- **Final completion:** 2020-04-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05140096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05140096, "A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05140096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*